Sana Biotechnology names new chief legal officer

Sana Biotechnology, Inc. reported a planned leadership transition in its top legal role.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Sana Biotechnology, Inc. reported a planned leadership transition in its top legal role. Executive Vice President, General Counsel, and Corporate Secretary Bernard J. Cassidy intends to retire, with his retirement expected to be effective on October 20, 2025, immediately before his successor starts work. After retiring from his executive positions, he is expected to continue providing transition-related services.

The company states that Mr. Cassidy’s retirement is voluntary, for personal reasons, and not due to any disagreement about its operations, policies, or practices. Sana has entered into an offer letter with Aaron M. Grossman, who is expected to begin on October 20, 2025, as Executive Vice President, Chief Legal Officer, succeeding Mr. Cassidy in leading the company’s legal function.

8-K Event Classification

2 items: 5.02, 8.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did Sana Biotechnology (SANA) disclose?

Sana Biotechnology disclosed that Bernard J. Cassidy plans to retire from his roles as Executive Vice President, General Counsel, and Corporate Secretary, and that Aaron M. Grossman is expected to become Executive Vice President, Chief Legal Officer.

When is Bernard J. Cassidy expected to retire from Sana Biotechnology (SANA)?

Bernard J. Cassidy’s retirement is expected to be effective on October 20, 2025, immediately before his successor commences employment with Sana Biotechnology.

Why is Sana Biotechnology’s Bernard J. Cassidy retiring?

Sana Biotechnology states that Bernard J. Cassidy’s retirement is voluntary and for personal reasons, and not the result of any disagreement with the company on its operations, policies, or practices.

Who will succeed Bernard J. Cassidy at Sana Biotechnology (SANA)?

Sana Biotechnology has entered into an offer letter with Aaron M. Grossman, who is expected to commence employment on October 20, 2025, as Executive Vice President, Chief Legal Officer.

Will Bernard J. Cassidy remain involved with Sana Biotechnology after retirement?

Following the effectiveness of his retirement, Sana Biotechnology expects that Bernard J. Cassidy will provide transition-related services to the company.

Does Sana Biotechnology link this leadership change to any disagreements or issues?

No. Sana Biotechnology specifies that Bernard J. Cassidy’s retirement is not due to any disagreement with the company regarding its operations, policies, practices, or other matters.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 09/05/2025 - 06:00 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 4, 2025

SANA BIOTECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)



Delaware	001-39941	83-1381173
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

188 East Blaine Street, Suite 400

Seattle, Washington 98102

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (206) 701-7914

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	SANA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Sana Biotechnology, Inc. (the “Company”) is filing this Current Report on Form 8-K (this “Current Report”) to disclose the planned retirement of Bernard J. Cassidy from his role as Executive Vice President, General Counsel, and Corporate Secretary. Mr. Cassidy’s retirement is expected to be effective on October 20, 2025, contingent upon and effective as of immediately prior to the commencement of his successor’s employment with the Company. Following the effectiveness of Mr. Cassidy’s retirement, the Company expects that Mr. Cassidy will provide transition-related services to the Company. Mr. Cassidy’s retirement is voluntary and for personal reasons, and is not a result of any disagreement with the Company on any matter, including the Company’s operations, policies, practices, or otherwise.

Item 8.01 Other Events.

In connection with Mr. Cassidy’s retirement described under Item 5.02 of this Current Report, the Company has entered into an offer letter with Aaron M. Grossman pursuant to which Mr. Grossman is expected to commence employment, effective as of October 20, 2025, as the Company’s Executive Vice President, Chief Legal Officer.

Cautionary Note Regarding Forward-Looking Statements

This Current Report contains forward-looking statements regarding Mr. Cassidy’s retirement and the commencement of Mr. Grossman's employment as his successor. These forward-looking statements reflect the Company’s current expectations and are based on currently available information. These forward-looking statements are not guarantees and are subject to risks, uncertainties, and assumptions that are difficult to predict, including with respect to the timing and effectiveness of the events contemplated in these forward-looking statements and certain other risks covered in the Risk Factors identified in the Company’s filings with the Securities and Exchange Commission ("SEC"), including the Company’s Annual Report on 10-K for the year ended December 31, 2024 and its Quarterly Report on Form 10-Q for the period ended June 30, 2025. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise. However, readers should carefully review the reports and documents the Company files or furnishes from time to time with the SEC, particularly its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	Sana Biotechnology, Inc.

Date: September 5, 2025	By:	/s/ Steven D. Harr, M.D.
		Steven D. Harr, M.D.
		President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR